Risk factor
Very high price volatility
Profitability factor
Very strong margins and returns
About
Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, an EGF eye drop for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Bokangtai, a mitiglinide tablet for the treatment of Type 2 diabetes, as well as Boshutai, an oral anti-diabetic drug targeting patients with pre-diabetes condition. It is also developing prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; and rhPTH 1-34 (Uni-PTH) for the treatment of osteoporosis in postmenopausal women, as well as Uni-GLP, a GLP-1 agonist, a non-insulin treatment candidate for the treatment of Type 2 diabetes. The company was founded in 2001 and is headquartered in Sha Tin, Hong Kong.
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, undervalued on P/FCF.
Buy
Sell